BRAF V 600E by IHC

BRAF V600E by IHC

What is the BRAF V600E by IHC Test?
BRAF V600E by Immunohistochemistry (IHC) is a tissue-based test that detects the presence of the BRAF V600E protein mutation in tumor cells. This mutation can help diagnose certain cancers, estimate prognosis, and identify patients who may benefit from targeted therapies.

Why is this test done?

• Detects the BRAF V600E mutation in tumor tissue.
• Supports accurate cancer diagnosis.
• Helps guide personalized treatment decisions.
• Assists in determining eligibility for BRAF-targeted therapy.
• May provide prognostic information in selected cancers.

Common Cancers Tested

• Melanoma
• Papillary thyroid carcinoma
• Colorectal carcinoma
• Hairy cell leukemia
• Langerhans cell histiocytosis
• Selected brain tumors and other solid tumors

Sample Required

• Formalin-fixed, paraffin-embedded (FFPE) tissue block or unstained tissue slides.

Benefits

• Rapid and reliable screening method.
• Uses routine pathology tissue samples.
• Helps identify candidates for targeted therapy.
• Supports precision oncology and treatment planning.

When is it recommended?

Doctors may recommend this test when a biopsy confirms or strongly suggests cancers in which BRAF V600E mutations are clinically significant, particularly before planning targeted treatment.

Caption

Targeted cancer treatment starts with accurate mutation testing. BRAF V600E by IHC helps identify key genetic changes that guide personalized cancer care.

#Dermafact #gynofact #BRAFV600E #IHC #CancerDiagnostics #PrecisionMedicine #TargetedTherapy #Oncology #Pathology #Biopsy #AdvancedDiagnostics #BioCareLaboratories